Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 10.91M | 9.50M | 8.95M | 14.70M | 3.90M | 773.00K |
Gross Profit | 10.65M | 9.16M | 8.27M | 13.97M | 2.47M | 388.00K |
EBITDA | -19.93M | -20.87M | -24.04M | -21.79M | -48.34M | -24.41M |
Net Income | -40.91M | -18.61M | -21.49M | -26.35M | -43.02M | -20.68M |
Balance Sheet | ||||||
Total Assets | 90.80M | 113.22M | 101.02M | 123.66M | 174.54M | 107.95M |
Cash, Cash Equivalents and Short-Term Investments | 42.29M | 47.80M | 35.49M | 57.88M | 58.36M | 41.56M |
Total Debt | 2.15M | 2.51M | 2.95M | 3.90M | 2.80M | 3.83M |
Total Liabilities | 43.69M | 36.21M | 39.00M | 51.73M | 83.65M | 12.82M |
Stockholders Equity | 48.38M | 78.38M | 63.42M | 73.34M | 92.22M | 96.20M |
Cash Flow | ||||||
Free Cash Flow | -22.85M | -23.66M | -29.24M | 646.00K | -23.91M | -19.82M |
Operating Cash Flow | -22.56M | -23.09M | -28.57M | 1.06M | -23.56M | -19.75M |
Investing Cash Flow | 8.41M | -2.31M | 46.45M | -46.16M | 9.74M | 13.04M |
Financing Cash Flow | 26.47M | 35.86M | 6.42M | 1.63M | 36.93M | 29.86M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
64 Neutral | $193.22M | ― | -48.36% | ― | 333.74% | ― | |
55 Neutral | $267.18M | ― | -70.12% | ― | 76.43% | -35.66% | |
51 Neutral | $7.86B | -0.33 | -41.57% | 2.23% | 23.26% | -2.03% | |
51 Neutral | $231.09M | ― | -188.58% | ― | -41.97% | -20.86% | |
39 Underperform | $150.57M | ― | -26.94% | ― | ― | 26.33% | |
39 Underperform | $293.04M | ― | -29.24% | ― | ― | -125.92% | |
33 Underperform | $280.17M | ― | -89.37% | ― | ― | 9.84% |
Lineage Cell Therapeutics announced a multi-year research collaboration with William Demant Invest 2 Aps to advance its auditory neuronal cell transplant program, ReSonance, aimed at treating hearing loss. The agreement, established on August 22, 2025, involves WDI funding up to $12 million over three years to achieve preclinical readiness for potential human clinical trials, with both parties sharing joint ownership of project results.
On June 26, 2025, Lineage Therap held its Annual Meeting, where shareholders elected seven directors to the board, ratified the appointment of Baker Tilly US, LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025, approved executive compensation on an advisory basis, and approved an EIP Amendment. These decisions reflect shareholder support for the company’s current leadership and strategic direction, potentially impacting its governance and financial practices.
Lineage Cell Therapeutics announced the 36-month visual acuity results from a Phase 1/2a clinical study of RG6501 (OpRegen) in patients with geographic atrophy secondary to age-related macular degeneration. The results, presented at Clinical Trials at the Summit 2025, showed sustained improvement in visual acuity and retinal structure in patients who received extensive OpRegen cell therapy coverage, suggesting potential long-term benefits of the therapy. These findings could enhance Lineage’s position in the biotechnology industry by demonstrating the efficacy of their cell therapy in treating advanced ophthalmic conditions.